Navigating The Road To Reality For Allogeneic Cell Therapies

“Off-the-shelf” allogeneic cell therapies offer the potential for groundbreaking cell-based treatments to be accessible to widespread populations of patients in need. Researchers, therapeutic developers, and manufacturers are working to chart this new path to patients, navigating unique challenges and considerations along the translational journey.

Here, we summarize highlights from our recent webinar, “The Road to Reality for Allogeneic Cell Therapy.” During this discussion, industry leaders shared insight into the key differences between autologous and allogeneic formulations along with special considerations for developing allogeneic treatments. We also outline actions researchers can take to look beyond the regulatory roadmap and efficiently move their allogeneic treatments from discovery to trial and the clinic, ensuring the translational journey ends with actual patient impact.